2.2 Eligibility for HFrEF trials 75 20. Scikit-Learn. Metrics: F1 score. Scikit-Learn n.d. https://scikitlearn/stable/modules/generated/sklearn.metrics.f1_score.html (accessed July 21, 2022). 21. Sen A, Goldstein A, Chakrabarti S, Shang N, Kang T, Yaman A, et al. The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0. J Am Med Inform Assoc 2018;25:239– 247. doi:10.1093/jamia/ocx091. 22. Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, et al. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Eur J Heart Fail 2016;18:716–726. doi:10.1002/ejhf.531. 23. Lam CSP, Anand I, Zhang S, Shimizu W, Narasimhan C, Park SW, et al. Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail 2013;15:928–936. doi:10.1093/eurjhf/hft045. 24. Sen A, Chakrabarti S, Goldstein A, Wang S, Ryan PB, Weng C. GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies. J Biomed Inform 2016;63:325–336. doi:10.1016/j.jbi.2016.09.003. 25. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software 2011;45:1–67. 26. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Statistics in Medicine 2011;30:377–399. doi:10.1002/sim.4067. 27. European Medicines Agency. Clinical trials submitted in marketing-authorisation applications to the European Medicines Agency. Overview of patient recruitment and the geographical location of investigator sites 2013. 28. Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP, et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. Am J Prev Cardiol 2021;8:100250. doi:10.1016/j.ajpc.2021.100250. 29. Bancroft C. Meeting Clinical Trial Data Requirements In Asian Markets 2020. https://www.clinicalleader.com/doc/meeting-clinical-trial-data-requirements-in-asian-markets0001 (accessed April 28, 2022). 30. Thorvaldsen T, Ferrannini G, Mellbin L, Benson L, Cosentino F, Mcmurray JJV, et al. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure 2022;28:1050–1062. doi:10.1016/j.cardfail.2022.04.011. 31. Chen X, Schaufelberger M, Fu M. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016. J Cardiovasc Med (Hagerstown) 2020;21:6–12. doi:10.2459/JCM.0000000000000889. 32. Oliveira Campinas A, Campos SC, Costa RC, Dias De Frias ADF, Alexandre AA, Gomes CG, et al. The representativeness of VICTORIA and GALACTIC-HF trials in a contemporary cohort of patients with heart failure with reduced ejection fraction. European Heart Journal 2021;42:ehab724.0779. doi:10.1093/eurheartj/ehab724.0779. 33. Clinical Trials Transformation Initiative. Researcher’s Guide to Using Aggregate Analysis of ClinicalTrials.gov (AACT) Database. Clinical Trials Transformation Initiative 2016. https://aact.ctticlinicaltrials.org/points_to_consider (accessed July 29, 2022). 34. Fiuzat M, Lowy N, Stockbridge N, Sbolli M, Latta F, Lindenfeld J, et al. Endpoints in Heart Failure Drug Development: History and Future. JACC Heart Fail 2020;8:429–440. doi:10.1016/j.jchf.2019.12.011. 35. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 2015;65:1668–1682. doi:10.1016/j.jacc.2015.03.043. 36. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L, et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014;16:103–111. doi:10.1002/ejhf.30.
RkJQdWJsaXNoZXIy MjY0ODMw